These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 31025123)

  • 1. The Use of Risk Assessment Tools and Prognostic Scores in Managing Patients with Pulmonary Arterial Hypertension.
    Kanwar M; Raina A; Lohmueller L; Kraisangka J; Benza R
    Curr Hypertens Rep; 2019 Apr; 21(6):45. PubMed ID: 31025123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypochloremia Is a Noninvasive Predictor of Mortality in Pulmonary Arterial Hypertension.
    Prins KW; Kalra R; Rose L; Assad TR; Archer SL; Bajaj NS; Weir EK; Prisco SZ; Pritzker M; Lutsey PL; Brittain EL; Thenappan T
    J Am Heart Assoc; 2020 Mar; 9(5):e015221. PubMed ID: 32079477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guideline implementation and early risk assessment in pulmonary arterial hypertension associated with congenital heart disease: A retrospective cohort study.
    Deng X; Jin B; Li S; Li Y; Zhou H; Wu Y; Yan M; Hu Y; Qiu Q; Zhang G; Zheng X
    Clin Respir J; 2019 Nov; 13(11):693-699. PubMed ID: 31419027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incorporation of renal function in mortality risk assessment for pulmonary arterial hypertension.
    Zelt JGE; Hossain A; Sun LY; Mehta S; Chandy G; Davies RA; Contreras-Dominguez V; Dunne R; Doyle-Cox C; Wells G; Stewart DJ; Mielniczuk LM
    J Heart Lung Transplant; 2020 Jul; 39(7):675-685. PubMed ID: 32336606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk stratification and prognostic factors in patients with pulmonary arterial hypertension and comorbidities a cross-sectional cohort study with survival follow-up.
    Xanthouli P; Koegler M; Marra AM; Benjamin N; Fischer L; Eichstaedt CA; Harutyunova S; Nagel C; Grünig E; Egenlauf B
    Respir Res; 2020 May; 21(1):127. PubMed ID: 32448256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-center prognostic validation of the risk assessment of the 2015 ESC/ERS guidelines in patients with pulmonary arterial hypertension in Japan.
    Imai R; Adachi S; Yoshida M; Shimokata S; Nakano Y; Okumura N; Murohara T; Kondo T
    Can J Physiol Pharmacol; 2020 Sep; 98(9):653-658. PubMed ID: 32924564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of the REVEAL Prognostic Equation and Risk Score Calculator in Incident Systemic Sclerosis-Associated Pulmonary Arterial Hypertension.
    Mullin CJ; Khair RM; Damico RL; Kolb TM; Hummers LK; Hassoun PM; Steen VD; Mathai SC;
    Arthritis Rheumatol; 2019 Oct; 71(10):1691-1700. PubMed ID: 31066998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction Models and Scores in Pulmonary Hypertension: A Review.
    Mouratoglou SA; Bayoumy AA; Noordegraaf AV
    Curr Pharm Des; 2021; 27(10):1266-1276. PubMed ID: 33155897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The combination of supervised and unsupervised learning based risk stratification and phenotyping in pulmonary arterial hypertension-a long-term retrospective multicenter trial.
    Sonnweber T; Tymoszuk P; Steringer-Mascherbauer R; Sigmund E; Porod-Schneiderbauer S; Kohlbacher L; Theurl I; Lang I; Weiss G; Löffler-Ragg J
    BMC Pulm Med; 2023 Apr; 23(1):143. PubMed ID: 37098543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mixed Venous Oxygen Saturation Is a Better Prognosticator Than Cardiac Index in Pulmonary Arterial Hypertension.
    Khirfan G; Almoushref A; Naal T; Abuhalimeh B; Dweik RA; Heresi GA; Tonelli AR
    Chest; 2020 Dec; 158(6):2546-2555. PubMed ID: 32629034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meaningful and feasible composite clinical worsening definitions in paediatric pulmonary arterial hypertension: An analysis of the TOPP registry.
    Beghetti M; Brand M; Berger RMF; Humpl T; Wheeler JG; Ivy DD; Bonnet D;
    Int J Cardiol; 2019 Aug; 289():110-115. PubMed ID: 31072635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk classification of pulmonary arterial hypertension by echocardiographic combined assessment of pulmonary vascular resistance and right ventricular function.
    Kawamukai M; Hashimoto A; Koyama M; Nagano N; Nishida J; Mochizuki A; Kouzu H; Muranaka A; Kokubu N; Nagahara D; Yuda S; Tsuchihashi K; Miura T
    Heart Vessels; 2019 Nov; 34(11):1789-1800. PubMed ID: 31119378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Risk factors for death and the clinical features of different subtypes of patients with pulmonary arterial hypertension related to congenital heart disease].
    Xu ZY; Li QQ; Zhang C; Zhang HS; Gu H
    Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Apr; 48(4):315-322. PubMed ID: 32370483
    [No Abstract]   [Full Text] [Related]  

  • 14. The role of serial right heart catheterization in risk stratification and management of pulmonary arterial hypertension.
    Sharma D; Shah RJ; Sreenivasan J; Kafle P; Gupta R; Levine A; Lanier GM; Aronow WS
    Expert Rev Cardiovasc Ther; 2022 Jul; 20(7):543-547. PubMed ID: 35726644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and survival impact of pulmonary arterial hypertension among patients with systemic lupus erythematosus: a nationwide cohort study.
    Chen HA; Hsu TC; Yang SC; Weng CT; Wu CH; Sun CY; Lin CY
    Arthritis Res Ther; 2019 Mar; 21(1):82. PubMed ID: 30917868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of Noninvasive Endpoints in Predicting Long-Term Outcomes in Pulmonary Arterial Hypertension.
    Wronski SL; Mordin M; Kelley K; Anguiano RH; Classi P; Shen E; Manaker S
    Lung; 2020 Feb; 198(1):65-86. PubMed ID: 31722043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Value of Follow-Up Hemodynamic Variables After Initial Management in Pulmonary Arterial Hypertension.
    Weatherald J; Boucly A; Chemla D; Savale L; Peng M; Jevnikar M; Jaïs X; Taniguchi Y; O'Connell C; Parent F; Sattler C; Hervé P; Simonneau G; Montani D; Humbert M; Adir Y; Sitbon O
    Circulation; 2018 Feb; 137(7):693-704. PubMed ID: 29070502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma markers in pulmonary hypertension subgroups correlate with patient survival.
    Koudstaal T; van Uden D; van Hulst JAC; Heukels P; Bergen IM; Geenen LW; Baggen VJM; van den Bosch AE; van den Toorn LM; Chandoesing PP; Kool M; Boersma E; Hendriks RW; Boomars KA
    Respir Res; 2021 May; 22(1):137. PubMed ID: 33947407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry.
    Boucly A; Weatherald J; Savale L; de Groote P; Cottin V; Prévot G; Chaouat A; Picard F; Horeau-Langlard D; Bourdin A; Jutant EM; Beurnier A; Jevnikar M; Jaïs X; Simonneau G; Montani D; Sitbon O; Humbert M
    Eur Respir J; 2022 Jun; 59(6):. PubMed ID: 34737227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With Pulmonary Arterial Hypertension.
    Benza RL; Kanwar MK; Raina A; Scott JV; Zhao CL; Selej M; Elliott CG; Farber HW
    Chest; 2021 Jan; 159(1):337-346. PubMed ID: 32882243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.